Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence

Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Christophe Le Tourneau(Institut Curie), Nicolas Mach(University of Geneva), Nati Lerman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Barbara Burtness(Yale University), Ramona F. Swaby(Merck & Co., Inc., Rahway, NJ, USA (United States)), Myung‐Ju Ahn(Sungkyunkwan University), Ranee Mehra(University of Maryland, Baltimore), Lisa Licitra(University of Milan), Denis Soulières(Centre Hospitalier de l’Université de Montréal), José Dinis(Instituto Português de Oncologia Francisco Gentil), Ainara Soria(Hospital Universitario Ramón y Cajal), Joy Yang Ge(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ezra E.W. Cohen(Moores Cancer Center), J.-P. Machiels(Cliniques Universitaires Saint-Luc), J. Lin(Merck & Co., Inc., Rahway, NJ, USA (United States))
Oral Oncology
November 3, 2023
10.1016/j.oraloncology.2023.106587
Cited by 17

Related Papers

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k